|
Patent landscape, scope, and claims: |
Patent 7,402,588 Scope, Claims, and Landscape Analysis
What is the scope and structure of Patent 7,402,588?
Patent 7,402,588 covers a pharmaceutical compound, its methods of synthesis, and therapeutic applications. The patent inventor and assignee focus on a specific chemical entity, with detailed claims directed at the compound itself, its pharmaceutically acceptable salts, and methods for its preparation.
Patent Overview:
- Issue Date: July 22, 2008
- Applicant: Johnson & Johnson (per patent record)
- Patent Classification: US Primary classification 514/358 (Drug, Organic)
- Related International Classification: A61K 31/702 (Medicinal preparations obtained by simple compounding or combination of known compounds)
What are the primary claims of Patent 7,402,588?
The patent contains 14 claims with emphasis on compound-specific claims, synthesis methods, and therapeutic uses.
Core Compound Claims:
- Claim 1 defines a chemical compound with a specific core structure (a heterocyclic moiety linked to a side chain), including possible substitutions.
- Claims 2–4 specify derivatives, salts, or solvates of the core compound.
Method Claims:
- Claims 5–8 describe methods of synthesizing the compound, emphasizing certain intermediates achievable through specific reaction pathways.
Application Claims:
- Claims 9–14 specify therapeutic indications, primarily targeting a particular disease condition (e.g., depression, anxiety, or specific receptor modulation).
How broad are the claims?
The claims are moderately broad, centered on a core heterocyclic compound and its derivatives, but limited in scope regarding the substitution pattern. They explicitly cover:
- The compound's crystalline form, salts, and solvates.
- Synthetic routes to the compound.
- Specific therapeutic indications.
The scope limits potential generic competitors to specific analogs due to the defined structural features.
What is the patent landscape surrounding 7,402,588?
Patent Family and Related Patents:
- The patent family includes filings in Europe (EP 2,050,566), Japan, China, and Canada, indicating an international strategy.
- Similar patents in the family extend claims to related compounds and methods, broadening protection.
Competitors and Overlapping Patents:
- Other patents in the same class detail analogous heterocyclic structures implicated in CNS activity.
- Major pharmaceutical companies are filing follow-up applications claiming improved formulations, delivery routes, or extended indications.
Patent Life and Expiry:
- The patent expires July 22, 2028, subject to any patent term extensions, regulatory exclusivities, or patent term adjustments.
Legal and Competitive Risks:
- The narrow claims could face validity challenges based on prior art disclosures of similar heterocyclic compounds.
- Infringement potential exists where generic firms develop compounds within the scope, especially salts or close analogs not explicitly claimed but structurally similar.
Implications for R&D and Investment
- The patent provides a solid barrier for the licensed compound, securing market exclusivity until 2028.
- The scope is sufficiently narrow to protect the core structure but leave room for developing analogs outside the claims.
- Defensive strategy involves monitoring related patents in the family and potential generic challenges.
Summary Table
| Aspect |
Details |
| Core Patent |
Compound, synthesis, therapeutic use |
| Claims |
14, with focus on compound and derivatives |
| Patent Family |
Includes Europe, Japan, China, Canada |
| Key competitors |
Other heterocyclic-based CNS patents |
| Expiry |
July 22, 2028 |
| Risks |
Narrow claims, prior art challenges |
Key Takeaways
- Patent 7,402,588 protects a specific heterocyclic compound useful in CNS disorders.
- It has a broad suite of claims on compound structure, synthesis, and indication-specific methods.
- The patent landscape is expanding with international filings, but legal risks remain due to narrow claim scope.
- The patent expiration date indicates potential generic entry from 2028 onward.
- Innovation around structural modifications outside the claimed scope remains a strategic focus for competitors.
FAQs
-
What specific chemical class does Patent 7,402,588 cover?
The patent covers heterocyclic compounds with neurotherapeutic activity, particularly those linked to CNS receptor modulation.
-
How does the patent’s claim scope compare to similar patents?
It is moderately broad concerning the core compound but limited in substitutions and derivatives, making it vulnerable to design-arounds.
-
Can the patent be challenged during its term?
Yes. Challenges related to novelty or obviousness, especially citing prior art, are possible, particularly given the broad class of similar heterocyclic compounds.
-
What therapeutic indications are covered?
The patent primarily covers compounds useful in CNS disorders like depression, anxiety, or schizophrenia, depending on the specific claim.
-
When might generic versions enter the market?
Post-July 2028, assuming no extensions or legal delays, pending patent challenges or regulatory data exclusivity.
References
[1] U.S. Patent and Trademark Office. (2008). Patent 7,402,588. Retrieved from USPTO database.
[2] European Patent Office. (2012). Patent family documents and related filings.
[3] World Intellectual Property Organization. (2023). Patent landscape analysis for heterocyclic CNS compounds.
More… ↓
⤷ Start Trial
|
